Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges
DS Krakower, KH Mayer - Drugs, 2015 - Springer
As the global incidence of HIV exceeds 2 million new infections annually, effective
interventions to decrease HIV transmission are needed. Randomized, placebo-controlled …
interventions to decrease HIV transmission are needed. Randomized, placebo-controlled …
[HTML][HTML] Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
J Gregson, M Tang, N Ndembi, RL Hamers… - The Lancet infectious …, 2016 - thelancet.com
Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through
wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir …
wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir …
[HTML][HTML] Drug resistance and virological failure among HIV-infected patients after a decade of antiretroviral treatment expansion in eight provinces of China
Z Zuo, S Liang, X Sun, S Bussell, J Yan, W Kan… - PLoS …, 2016 - journals.plos.org
Background China's National Free Antiretroviral Treatment Program (NFATP) has
substantially increased the survival rate since 2002. However, the emergence of HIV drug …
substantially increased the survival rate since 2002. However, the emergence of HIV drug …
High levels of pre‐treatment HIV drug resistance and treatment failure in Nigerian children
RS Boerma, TS Boender, KCE Sigaloff… - Journal of the …, 2016 - Wiley Online Library
Introduction Pre‐treatment HIV drug resistance (PDR) is an increasing problem in sub‐
Saharan Africa. Children are an especially vulnerable population to develop PDR given that …
Saharan Africa. Children are an especially vulnerable population to develop PDR given that …
[HTML][HTML] High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa
L Skhosana, K Steegen, M Bronze, A Lukhwareni… - PloS one, 2015 - journals.plos.org
Background Tenofovir (TDF) has replaced stavudine (d4T) as the preferred nucleoside
reverse transcriptase inhibitor (NRTI) in first-line regimens in South Africa, but limited …
reverse transcriptase inhibitor (NRTI) in first-line regimens in South Africa, but limited …
[HTML][HTML] Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study
YA Scriven, MM Mulinge, N Saleri, EA Luvai… - Medicine, 2021 - journals.lww.com
An estimated 1.5 million Kenyans are HIV-seropositive, with 1.1 million on antiretroviral
therapy (ART), with the majority of them unaware of their drug resistance status. In this study …
therapy (ART), with the majority of them unaware of their drug resistance status. In this study …
Treatment failure and drug resistance in HIV‐positive patients on tenofovir‐based first‐line antiretroviral therapy in western Kenya
K Brooks, L Diero, A DeLong… - Journal of the …, 2016 - Wiley Online Library
Introduction Tenofovir‐based first‐line antiretroviral therapy (ART) is recommended globally.
To evaluate the impact of its incorporation into the World Health Organization (WHO) …
To evaluate the impact of its incorporation into the World Health Organization (WHO) …
[HTML][HTML] An analysis of drug resistance among people living with HIV/AIDS in Shanghai, China
F Zhang, L Liu, M Sun, J Sun, H Lu - PLoS One, 2017 - journals.plos.org
Background Understanding the mechanisms of drug resistance can facilitate better
management of antiretroviral therapy, helping to prevent transmission and decrease the …
management of antiretroviral therapy, helping to prevent transmission and decrease the …
Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review
V Vannappagari, L Ragone, C Henegar… - Antiviral …, 2019 - journals.sagepub.com
Background Pretreatment and acquired drug resistance mutations (DRMs) can limit
antiretroviral therapy effectiveness. Methods We review prevalence of DRMs with resistance …
antiretroviral therapy effectiveness. Methods We review prevalence of DRMs with resistance …
[HTML][HTML] HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa
C Kityo, J Thompson, I Nankya, A Hoppe… - JAIDS Journal of …, 2017 - journals.lww.com
Objective: To determine drug resistance mutation (DRM) patterns in a large cohort of
patients failing nonnucleoside reverse transcriptase inhibitor (NNRTI)-based first-line …
patients failing nonnucleoside reverse transcriptase inhibitor (NNRTI)-based first-line …